Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer

Targeted therapies have increased the treatment options for triple-negative breast cancer patients. However, the paucity of targetable biomarkers and tumor heterogeneity have limited the ability of precision-guided interventions to live up to their full potential. As affinity-targeting ligands, apta...

Descripción completa

Detalles Bibliográficos
Autores principales: Pleiko, Karlis, Haugas, Maarja, Parfejevs, Vadims, Pantelejevs, Teodors, Parisini, Emilio, Teesalu, Tambet, Riekstina, Una
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481362/
https://www.ncbi.nlm.nih.gov/pubmed/37680989
http://dx.doi.org/10.1016/j.omtn.2023.08.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481362/
https://www.ncbi.nlm.nih.gov/pubmed/37680989
http://dx.doi.org/10.1016/j.omtn.2023.08.015

Ejemplares similares